Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Elevation of Serum CEA in Patients with Squamous Cell Carcinoma of the Anus.

Raab GT, O'Neil DS, Kiran RP, Feingold DL, Lee-Kong SA, Horowitz DP, Neugut AI.

Cancer Invest. 2019 Jul 18:1-5. doi: 10.1080/07357907.2019.1636388. [Epub ahead of print]

PMID:
31319725
2.

Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.

Raab GT, Lin A, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Buono DL, Hur C, Kiran RP, Wright JD, Hershman DL, Neugut AI.

Clin Colorectal Cancer. 2019 Jun 8. pii: S1533-0028(19)30157-4. doi: 10.1016/j.clcc.2019.05.008. [Epub ahead of print]

PMID:
31266707
3.

FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.

Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Kiran RP, Wright J, Hershman DL.

Clin Colorectal Cancer. 2019 Jun;18(2):133-140. doi: 10.1016/j.clcc.2019.01.005. Epub 2019 Jan 31.

PMID:
30878317
4.

Does equality legislation reduce intergroup differences? Religious affiliation, socio-economic status and mortality in Scotland and Northern Ireland: A cohort study of 400,000 people.

Wright DM, Rosato M, Raab G, Dibben C, Boyle P, O'Reilly D.

Health Place. 2017 May;45:32-38. doi: 10.1016/j.healthplace.2017.02.009. Epub 2017 Mar 6.

PMID:
28279905
5.

Mortality differences and inequalities within and between 'protected characteristics' groups, in a Scottish Cohort 1991-2009.

Millard AD, Raab G, Lewsey J, Eaglesham P, Craig P, Ralston K, McCartney G.

Int J Equity Health. 2015 Nov 25;14:142. doi: 10.1186/s12939-015-0274-8.

6.

DataSHIELD: taking the analysis to the data, not the data to the analysis.

Gaye A, Marcon Y, Isaeva J, LaFlamme P, Turner A, Jones EM, Minion J, Boyd AW, Newby CJ, Nuotio ML, Wilson R, Butters O, Murtagh B, Demir I, Doiron D, Giepmans L, Wallace SE, Budin-Ljøsne I, Oliver Schmidt C, Boffetta P, Boniol M, Bota M, Carter KW, deKlerk N, Dibben C, Francis RW, Hiekkalinna T, Hveem K, Kvaløy K, Millar S, Perry IJ, Peters A, Phillips CM, Popham F, Raab G, Reischl E, Sheehan N, Waldenberger M, Perola M, van den Heuvel E, Macleod J, Knoppers BM, Stolk RP, Fortier I, Harris JR, Woffenbuttel BH, Murtagh MJ, Ferretti V, Burton PR.

Int J Epidemiol. 2014 Dec;43(6):1929-44. doi: 10.1093/ije/dyu188. Epub 2014 Sep 26.

7.

Association between socioeconomic factors and cancer risk: a population cohort study in Scotland (1991-2006).

Sharpe KH, McMahon AD, Raab GM, Brewster DH, Conway DI.

PLoS One. 2014 Feb 27;9(2):e89513. doi: 10.1371/journal.pone.0089513. eCollection 2014.

8.

Does widowhood increase mortality risk?: testing for selection effects by comparing causes of spousal death.

Boyle PJ, Feng Z, Raab GM.

Epidemiology. 2011 Jan;22(1):1-5. doi: 10.1097/EDE.0b013e3181fdcc0b.

PMID:
21052007
9.

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, Ruckley CV, Raab GM; BASIL Trial Participants.

J Vasc Surg. 2010 May;51(5 Suppl):52S-68S. doi: 10.1016/j.jvs.2010.01.077. Erratum in: J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Battacharya, V].

10.

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis.

Forbes JF, Adam DJ, Bell J, Fowkes FG, Gillespie I, Raab GM, Ruckley CV, Bradbury AW; BASIL trial Participants.

J Vasc Surg. 2010 May;51(5 Suppl):43S-51S. doi: 10.1016/j.jvs.2010.01.076.

11.

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, Ruckley CV, Raab GM; BASIL trial Participants.

J Vasc Surg. 2010 May;51(5 Suppl):32S-42S. doi: 10.1016/j.jvs.2010.01.075. Erratum in: J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Bhattacharya, V].

12.

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, Ruckley CV, Raab GM; BASIL trial Participants.

J Vasc Surg. 2010 May;51(5 Suppl):18S-31S. doi: 10.1016/j.jvs.2010.01.074. Erratum in: J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Bhattacharya, V].

13.

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, Ruckley CV, Raab GM; BASIL trial Participants.

J Vasc Surg. 2010 May;51(5 Suppl):5S-17S. doi: 10.1016/j.jvs.2010.01.073. Erratum in: J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Bhattacharya, V].

14.

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A.

Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19.

PMID:
20389141
16.

Modelling individual space-time exposure opportunities: a novel approach to unravelling the genetic or environment disease causation debate.

Sabel CE, Boyle P, Raab G, Löytönen M, Maasilta P.

Spat Spatiotemporal Epidemiol. 2009 Oct-Dec;1(1):85-94. doi: 10.1016/j.sste.2009.07.002. Epub 2009 Aug 11.

PMID:
22749415
17.

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.

Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L.

Anticancer Drugs. 2009 Aug;20(7):616-24.

PMID:
19739318
18.

When are summary ROC curves appropriate for diagnostic meta-analyses?

Chappell FM, Raab GM, Wardlaw JM.

Stat Med. 2009 Sep 20;28(21):2653-68. doi: 10.1002/sim.3631.

PMID:
19591118
19.

Aspiration as an aid to the diagnosis of prosthetic knee instability.

Raab GE, Fehring TK, Odum SM, Mason JB, Griffin WL.

Orthopedics. 2009 May;32(5):318.

PMID:
19472970
20.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G.

J Clin Oncol. 2009 May 20;27(15):2474-81. doi: 10.1200/JCO.2008.19.2567. Epub 2009 Mar 30.

PMID:
19332727
21.

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.

Lux MP, Hartmann M, Jackisch C, Raab G, Schneeweiss A, Possinger K, Oyee J, Harbeck N.

Breast Cancer Res Treat. 2009 Sep;117(2):305-17. doi: 10.1007/s10549-008-0294-9. Epub 2009 Jan 8.

PMID:
19130218
22.

Cohort Profile: the Scottish Longitudinal Study (SLS).

Boyle PJ, Feijten P, Feng Z, Hattersley L, Huang Z, Nolan J, Raab G.

Int J Epidemiol. 2009 Apr;38(2):385-92. doi: 10.1093/ije/dyn087. Epub 2008 May 20. No abstract available.

PMID:
18492728
23.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

24.

What explains between-school differences in rates of sexual experience?

Henderson M, Butcher I, Wight D, Williamson L, Raab G.

BMC Public Health. 2008 Feb 8;8:53. doi: 10.1186/1471-2458-8-53.

25.

Randomized trial of essential oils to reduce perioperative patient anxiety: feasibility study.

Stirling L, Raab G, Alder EM, Robertson F.

J Adv Nurs. 2007 Dec;60(5):494-501.

PMID:
17973713
26.

Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial.

Müller C, Caputo A, Schumacher M, Raab G, Schütte M, Hilfrich J, Kaufmann M, von Minckwitz G.

Eur J Cancer. 2007 Jul;43(11):1654-61. Epub 2007 Jun 4.

PMID:
17544652
27.

Technical improvement of pO(2) measurements in breast cancer: investigation of the feasibility in patients and in vitro validation of the method.

Auer F, Röper B, Scheich D, Molls M, Eiermann W, Raab G.

Strahlenther Onkol. 2007 May;183(5):265-70.

PMID:
17497098
28.
29.
31.

Randomized comparison of dry dressings versus hydrogel in management of radiation-induced moist desquamation.

Macmillan MS, Wells M, MacBride S, Raab GM, Munro A, MacDougall H.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):864-72. Epub 2007 Mar 23.

PMID:
17363185
32.

Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.

Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A.

Addiction. 2006 Dec;101(12):1752-9.

PMID:
17156174
33.
34.

Analysing sequential events in clinical trials.

Salter A, Raab G, Day S.

Clin Trials. 2006;3(5):421-30. Erratum in: Clin Trials. 2007;4(1):106.

PMID:
17060216
35.

The Bysl gene product, bystin, is essential for survival of mouse embryos.

Aoki R, Suzuki N, Paria BC, Sugihara K, Akama TO, Raab G, Miyoshi M, Nadano D, Fukuda MN.

FEBS Lett. 2006 Nov 13;580(26):6062-8. Epub 2006 Oct 16.

36.

Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.

Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, Eidtmann H, Petrich S, Hilfrich J, Jackisch C, du Bois A, Kaufmann M.

Ann Surg Oncol. 2006 Nov;13(11):1434-42. Epub 2006 Sep 17.

PMID:
16983592
37.

On the species-specific biotransformation of dibenzo[a,l]pyrene.

Schober W, Luch A, Soballa VJ, Raab G, Stegeman JJ, Doehmer J, Jacob J, Seidel A.

Chem Biol Interact. 2006 May 15;161(1):37-48. Epub 2006 Apr 11.

PMID:
16581046
38.

Early healing with locked condylar plating of periprosthetic fractures around the knee.

Raab GE, Davis CM 3rd.

J Arthroplasty. 2005 Dec;20(8):984-9.

PMID:
16376252
39.

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.

Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21.

40.

Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.

Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants.

Lancet. 2005 Dec 3;366(9501):1925-34.

PMID:
16325694
41.

Randomization inference for balanced cluster-randomized trials.

Raab GM, Butcher I.

Clin Trials. 2005;2(2):130-40.

PMID:
16279135
42.

Cytotoxic assays for screening anticancer agents.

Baharith LA, Al-Khouli A, Raab GM.

Stat Med. 2006 Jul 15;25(13):2323-39.

PMID:
16013035
43.

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.

von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M.

J Clin Oncol. 2005 Apr 20;23(12):2676-85.

PMID:
15837982
44.

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD; German Breast Group.

Ann Oncol. 2005 Jan;16(1):56-63.

PMID:
15598939
45.

Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial.

Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, MacDougall H, Samuel L, Munro A.

Radiother Oncol. 2004 Nov;73(2):153-62.

PMID:
15542162
46.

Designing follow-up intervals.

Raab GM, Davies JA, Salter AB.

Stat Med. 2004 Oct 30;23(20):3125-37.

PMID:
15449335
47.

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.

Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Viganò L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, Baselga J.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5944-51.

48.

Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function.

Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3221-6. Epub 2003 Mar 5.

49.

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.

Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schütte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A, Kaufmann M.

Clin Breast Cancer. 2002 Oct;3(4):276-80.

PMID:
12425756
50.

Supplemental Content

Support Center